Choosing Drugs for Relapsed Myeloma Treatment

The question asks for a suitable drug combination for treating relapsed myeloma. Relapsed myeloma refers to the return of multiple myeloma after a period of improvement.

Evaluating Treatment Options

• Option 1: Infliximab, Methotrexate, Dexamethasone - Infliximab targets TNF-alpha and is not a standard treatment for myeloma. Methotrexate is used in some cancers but not typically first-line for myeloma.
• Option 2: Lenalidomide, Bortezomib, Dexamethasone - This combination is a standard and effective treatment approach for relapsed multiple myeloma.
  • Lenalidomide: An immunomodulatory drug (IMiD) that helps the immune system attack myeloma cells and can directly slow their growth.
  • Bortezomib: A proteasome inhibitor that blocks protein degradation pathways in cancer cells, leading to their death.
  • Dexamethasone: A corticosteroid that reduces inflammation and has direct anti-myeloma effects.
• Option 3: Rituximab, Vincristine, Cytarabine - Rituximab targets CD20, primarily used for B-cell lymphomas, not standard for myeloma. Vincristine and Cytarabine can be used in some myeloma regimens but are less common in this specific combination for relapsed disease compared to Option 2.
• Option 4: Methotrexate, Doxorubicin, Prednisone - While Doxorubicin and Prednisone (a steroid similar to Dexamethasone) are used in myeloma, Methotrexate is not a standard component for treating relapsed myeloma.

Conclusion on Relapsed Myeloma Therapy

The combination of Lenalidomide, Bortezomib, and Dexamethasone represents a widely accepted and effective standard of care for patients experiencing relapsed multiple myeloma due to the synergistic action and proven efficacy of these agents against the disease.